Ivan Hyep Sells 6,514 Shares of Bicara Therapeutics (NASDAQ:BCAX) Stock

Key Points

• CFO Ivan Hyep sold a total of 6,514 shares of Bicara Therapeutics stock on October 6th, reducing his ownership by 4.29% to 145,355 shares.
• The stock's performance includes a recent trading price of $18.00 and a market cap of approximately $982.98 million, with a fifty-two week range between $7.80 and $28.09.
• Recent analyst ratings vary, with the average rating being a "Moderate Buy" and a consensus target price of $31.86 reflecting positive expectations for the company.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) CFO Ivan Hyep sold 6,514 shares of the firm's stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $18.17, for a total value of $118,359.38. Following the completion of the transaction, the chief financial officer owned 145,355 shares in the company, valued at approximately $2,641,100.35. This represents a 4.29% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Ivan Hyep also recently made the following trade(s):

• On Tuesday, October 7th, Ivan Hyep sold 18,244 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.22, for a total value of $332,405.68.
• On Wednesday, October 8th, Ivan Hyep sold 5,627 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.21, for a total value of $102,467.67.

Bicara Therapeutics Stock Performance

NASDAQ:BCAX traded down $0.17 during mid-day trading on Wednesday, hitting $18.00. The company had a trading volume of 514,631 shares, compared to its average volume of 579,256. The firm has a market cap of $982.98 million and a P/E ratio of -5.68. The business's fifty day moving average is $12.09 and its two-hundred day moving average is $11.76. Bicara Therapeutics Inc. has a fifty-two week low of $7.80 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.04. Equities analysts forecast that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. California State Teachers Retirement System acquired a new position in Bicara Therapeutics in the 4th quarter valued at $25,000. CWM LLC acquired a new position in Bicara Therapeutics in the 1st quarter valued at $29,000. Legal & General Group Plc raised its holdings in Bicara Therapeutics by 64.1% in the 2nd quarter. Legal & General Group Plc now owns 3,156 shares of the company's stock valued at $29,000 after acquiring an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. raised its holdings in Bicara Therapeutics by 73.0% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company's stock valued at $32,000 after acquiring an additional 1,474 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company's stock worth $44,000 after buying an additional 3,866 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. Wedbush reissued an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Tuesday, August 12th. HC Wainwright decreased their price target on Bicara Therapeutics from $41.00 to $40.00 and set a "buy" rating for the company in a research note on Friday, August 22nd. Piper Sandler assumed coverage on Bicara Therapeutics in a research note on Monday, August 18th. They issued an "overweight" rating and a $36.00 price target for the company. Finally, Weiss Ratings reissued a "sell (e+)" rating on shares of Bicara Therapeutics in a report on Saturday, September 27th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $31.86.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.